Karin Yaacoby-Bianu1,2, Zeev Schnapp2,3, Ilana Koren2,4, Anat Ilivitzki2,5, Mohamed Khatib2, Nadeem Shorbaji2, Michal Shteinberg2,6, Galit Livnat7,8. 1. Pediatric Pulmonology Unit and CF Center, Carmel Medical Center, 7 Michal St, 3436212, Haifa, Israel. 2. B. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. 3. Department of Pediatrics, Carmel Medical Center, Haifa, Israel. 4. Pediatric Endocrinology Unit, Carmel Medical Center, Haifa, Israel. 5. Pediatric Radiology Unit, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel. 6. Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel. 7. Pediatric Pulmonology Unit and CF Center, Carmel Medical Center, 7 Michal St, 3436212, Haifa, Israel. galitlivlev@gmail.com. 8. B. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. galitlivlev@gmail.com.
Abstract
BACKGROUND: Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508del homozygous CF patients. However, the systemic effects of LUM-IVA outside the respiratory system have not yet been thoroughly investigated. METHODS: A prospective, real-world, yearlong study was performed on F508del homozygous adult CF patients who commenced treatment with LUM-IVA. Pancreatic function, bone metabolism, fertility status, nutritional and pulmonary factors were evaluated. RESULTS: Twelve patients, mean age 28.3 years (18.6-43.9) were recruited. Following 12 months of treatment, no changes were detected in glucose, insulin, c-peptide or BMI values. A significant relative decrease in mean alkaline-phosphatase levels (122.8 U/L vs 89.4, p = 0.002) and a trend toward an increase in calcium levels (9.5 vs 9.9 mg/dL, p = 0.074) were observed. A non-significant improvement in mean DEXA spine t-score after a year of treatment (-2.1 vs -1.6, n = 4, p = 0.11) was detected. Sweat chloride concentrations decreased significantly (-21.4 mEq/L; p = 0.003). Pulmonary outcome revealed improvement in spirometry values during the first three months (FEV1 by 5.7% p = 0.009, FEF25-75 by 4.3% p = 0.001) with no change in chest CT Bhalla score and CFQR after one year. There was also a significant decrease in parenteral antibiotic events (17 vs 8, p = 0.039) with shift from IV to oral antibiotics for PEx treatment. CONCLUSIONS: After one year of treatment, stabilization was observed in the pancreatic indices, nutritional status, structure and function of the lungs, with a beneficial effect on bone mineral metabolism and CFTR function. Additional studies should investigate the effect of CFTR modulators on extra-pulmonary manifestations.
BACKGROUND: Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508del homozygous CF patients. However, the systemic effects of LUM-IVA outside the respiratory system have not yet been thoroughly investigated. METHODS: A prospective, real-world, yearlong study was performed on F508del homozygous adult CF patients who commenced treatment with LUM-IVA. Pancreatic function, bone metabolism, fertility status, nutritional and pulmonary factors were evaluated. RESULTS: Twelve patients, mean age 28.3 years (18.6-43.9) were recruited. Following 12 months of treatment, no changes were detected in glucose, insulin, c-peptide or BMI values. A significant relative decrease in mean alkaline-phosphatase levels (122.8 U/L vs 89.4, p = 0.002) and a trend toward an increase in calcium levels (9.5 vs 9.9 mg/dL, p = 0.074) were observed. A non-significant improvement in mean DEXA spine t-score after a year of treatment (-2.1 vs -1.6, n = 4, p = 0.11) was detected. Sweat chloride concentrations decreased significantly (-21.4 mEq/L; p = 0.003). Pulmonary outcome revealed improvement in spirometry values during the first three months (FEV1 by 5.7% p = 0.009, FEF25-75 by 4.3% p = 0.001) with no change in chest CT Bhalla score and CFQR after one year. There was also a significant decrease in parenteral antibiotic events (17 vs 8, p = 0.039) with shift from IV to oral antibiotics for PEx treatment. CONCLUSIONS: After one year of treatment, stabilization was observed in the pancreatic indices, nutritional status, structure and function of the lungs, with a beneficial effect on bone mineral metabolism and CFTR function. Additional studies should investigate the effect of CFTR modulators on extra-pulmonary manifestations.
Authors: B L Aalbers; K M de Winter-de Groot; H G M Arets; R W Hofland; A C de Kiviet; M M M van Oirschot-van de Ven; M A Kruijswijk; S Schotman; S Michel; C K van der Ent; H G M Heijerman Journal: J Cyst Fibros Date: 2020-01-07 Impact factor: 5.482
Authors: Nicola J Ronan; Gisli G Einarsson; Maria Twomey; Denver Mooney; David Mullane; Muireann NiChroinin; Grace O'Callaghan; Fergus Shanahan; Desmond M Murphy; Owen J O'Connor; Cathy A Shortt; Michael M Tunney; Joseph A Eustace; Michael M Maher; J Stuart Elborn; Barry J Plant Journal: Chest Date: 2017-10-14 Impact factor: 9.410
Authors: Angel Li; Tim Vigers; Laura Pyle; Edith Zemanick; Kristen Nadeau; Scott D Sagel; Christine L Chan Journal: J Cyst Fibros Date: 2018-08-10 Impact factor: 5.482
Authors: Leona Bessonova; Nataliya Volkova; Mark Higgins; Leif Bengtsson; Simon Tian; Christopher Simard; Michael W Konstan; Gregory S Sawicki; Ase Sewall; Stephen Nyangoma; Alexander Elbert; Bruce C Marshall; Diana Bilton Journal: Thorax Date: 2018-05-10 Impact factor: 9.139